✦ In a proposed rule issued on May 26, CMS delayed for six months a provision in a Trump administration-era rule that would have required drug manufacturers to report multiple Medicaid “best prices” connected to a value-based purchasing arrangement. The rule, finalized on Dec. 31, 2020, altered Medicaid “best price” rules — which dictate how rebates are calculated in the Medicaid Drug Rebate Program — by clarifying best price reporting requirements and enabling new models including year-to-year scheduled prices that could change in relation to patient outcomes.
✦ Thousands of health plans that sought to make their lawsuits against Cigna Corp. into a class action were stymied by a federal judge on May 20, according to a Modern Healthcare article. The self-funded health plans alleged that Cigna overcharged their members for prescription drugs by secretly clawing back the difference when a given drug costs less than a patient’s copayment amount and prohibiting pharmacists from telling patients their drugs could cost less without insurance. U.S. District Judge Jeffery Alker Meyer said plan contracts varied too widely for a class-wide ruling.